[Solved] Diagnostics wk 12 reply

✓ Verified Academic Solution Available

Executive Solution Overview

Please write a 300 word reply to my classmate, her discussion post is below. APA format. NO AI. My professor is a stickler for AI. PLEASE NO AI. scholarly written, APA formatted and a minimum of 3 references. "Irina: **Case Summary and Clinical Management: Herpes Zoster** ## **Case Summary** **Patie…

Instant Solution Download

$6.99

Immediate access to the full model answer, formatted citations, and rubric breakdown.

Need a Fresh Custom Paper?

Have this question answered from scratch according to your specific instructions and deadline.

Order on TutorsGallery →

Assignment Prompt & Instructions

Please write a 300 word reply to my classmate, her discussion post is below. APA format. NO AI. My professor is a stickler for AI. PLEASE NO AI. scholarly written, APA formatted and a minimum of 3 references.

"Irina: **Case Summary and Clinical Management: Herpes Zoster**

## **Case Summary**

**Patient:** 65-year-old man

**Chief Complaints:** Sharp, burning left lower back pain radiating to the flank and abdomen (3-day duration); electric shock-like dysesthesia unrelated to physical activity; and a new-onset unilateral vesicular rash in the same distribution.

## **1. Probable Diagnosis**

Herpes Zoster (Shingles) — Reactivation of Varicella-Zoster Virus (VZV)

**Feature**

**Supporting Evidence**

Demographics

Age 65; risk for herpes zoster and complications increases sharply after 50 years due to declining VZV-specific cell-mediated immunity.

Pain Prodrome

3 days of severe, burning, electric shock-like neuropathic pain preceding the rash — classic for VZV reactivation.

Dermatomal Distribution

Unilateral eruption extending from the left lower back to the midline of the abdomen, strictly respecting the midline.

Rash Morphology

Patches of erythema with grouped vesicles on an erythematous base localized to the painful dermatome.

## **2. Other Possible Diagnoses**

**Differential**

**Key Distinguishing Features**

Herpes Simplex Virus (HSV)

Zosteriform HSV presents with grouped vesicles but is usually more localized and recurrent in the same spot.

Contact Dermatitis

Presents with erythema and vesicles but is intensely pruritic rather than painful; history of allergen exposure.

Cellulitis

Characterized by spreading erythema, warmth, and swelling; lacks grouped vesicles and dermatomal pattern.

Bullous Impetigo

Presents with flaccid bullae and honey-colored crusts; usually not painful and lacks dermatomal distribution.

Dermatitis Herpetiformis

Intensely pruritic grouped vesicles on extensor surfaces bilaterally; associated with celiac disease.

## **3. Diagnostic Studies and Rationale**

**Diagnostic Study**

**Rationale**

Clinical Evaluation

Diagnosis is primarily clinical based on characteristic unilateral, dermatomal vesicular rash.

PCR (Vesicular Fluid)

Most sensitive and specific test for VZV DNA; indicated if the presentation is atypical.

Tzanck Smear

Demonstrates multinucleated giant cells; cannot distinguish VZV from HSV; less accurate than PCR.

Direct Fluorescent Antibody

Rapid identification of viral antigens; less sensitive than PCR.

Renal Function Panel

Baseline assessment prior to initiating antiviral therapy (e.g., acyclovir).

## **4. Basic Treatments and Rationale**

– **Antiviral Therapy:** Initiated within 72 hours to accelerate healing and reduce Postherpetic Neuralgia (PHN) risk.
– **Pain Management:** NSAIDs or Acetaminophen for mild pain and inflammation control.
– **Neuropathic Agents:** Gabapentin or Pregabalin for moderate-to-severe neuropathic pain.
– **Topical Therapy:** Calamine lotion or cool wet compresses to soothe skin and promote drying.
– **Infection Control:** Covering the rash to prevent transmission of VZV via direct contact.

## **5. Key Clinical Priorities**

1. Initiate antivirals immediately (within 72 hours).
2.  Assess for complications (e.g., disseminated zoster, ocular involvement).
3. Aggressive pain control to prevent chronic PHN.
4. Infection control counseling regarding susceptible contacts.
5. Post-recovery vaccination with Shingrix."

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *